"Pavl\u00EDk, Tom\u00E1\u0161" . . . . "10.1186/1471-2458-12-117" . "http://www.biomedcentral.com/1471-2458/12/117" . . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . . . "Mu\u017E\u00EDk, Jan" . "12" . "I, N, P(GD102/09/H083), P(NS10650)" . . . . "%22art. 117%22" . . . "Du\u0161ek, Ladislav" . "M\u00E1jek, Ond\u0159ej" . . . "Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry" . "Colorectal cancer (CRC) represents a serious health care problem in the Czech Republic, introducing a need for a prospective modelling of the incidence and prevalence rates. The prevalence of patients requiring anti-tumour therapy is also of great importance, as it is directly associated with planning of health care resources. Methods This work proposes a population-based model for the estimation of stage-specific prevalence of CRC patients who will require active anti-tumour therapy in a given year. Its applicability is documented on records of the Czech National Cancer Registry (CNCR), which is used to estimate the number of patients potentially treated with anti-tumour therapy in the Czech Republic in 2015. Results Several scenarios are adopted to cover the plausible development of the incidence and survival rates, and the probability of an anti-tumour therapy initiation." . "F\u00EDnek, Jind\u0159ich" . "Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry"@en . . . "Vyzula, Rostislav" . "Kopt\u00EDkov\u00E1, Jana" . . . "RIV/00216224:14110/12:00057270" . "134769" . "BMC Public Health" . . . "000302376800001" . "RIV/00216224:14110/12:00057270!RIV13-GA0-14110___" . . "Colorectal cancer (CRC) represents a serious health care problem in the Czech Republic, introducing a need for a prospective modelling of the incidence and prevalence rates. The prevalence of patients requiring anti-tumour therapy is also of great importance, as it is directly associated with planning of health care resources. Methods This work proposes a population-based model for the estimation of stage-specific prevalence of CRC patients who will require active anti-tumour therapy in a given year. Its applicability is documented on records of the Czech National Cancer Registry (CNCR), which is used to estimate the number of patients potentially treated with anti-tumour therapy in the Czech Republic in 2015. Results Several scenarios are adopted to cover the plausible development of the incidence and survival rates, and the probability of an anti-tumour therapy initiation."@en . . "14110" . "10"^^ . "[AC536329F145]" . "Feltl, David" . . . . "Slav\u00ED\u010Dek, Lubom\u00EDr" . . "PREOPERATIVE RADIOTHERAPY; PREVALENCE; POPULATION; CARE; PATTERNS; FRANCE; STAGE; PROJECTIONS; PREDICTION; RECURRENCE"@en . "1471-2458" . . "Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry"@en . "Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry" . . . "9"^^ . . . . . "8"^^ . .